Collateral sensitivity networks reveal evolutionary instability and novel treatment strategies in ALK mutated non-small cell lung cancer

Exploiting Temporal Collateral Sensitivity in Tumor Clonal Evolution

(2016) Boyang Zhao et al.   CELL

Stochasticity in the Genotype-Phenotype Map: Implications for the Robustness and Persistence of Bet-Hedging

(2016) Daniel Nichol et al.   GENETICS

Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F

(2016) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

Stochasticity in the Genotype-Phenotype Map: Implications for the Robustness and Persistence of Bet-Hedging

(2016) Daniel Nichol et al.   GENETICS

Metronomic chemotherapy: An attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance

(2015) Irina Kareva et al.   CANCER LETTERS

Rational Design of Antibiotic Treatment Plans: A Treatment Strategy for Managing Evolution and Reversing Resistance

(2015) Portia M. Mira et al.   PLoS One

Collateral sensitivity of antibiotic-resistant microbes

(2015) Csaba Pál et al.   TRENDS IN MICROBIOLOGY

Steering Evolution with Sequential Therapy to Prevent the Emergence of Bacterial Antibiotic Resistance

(2015) Daniel Nichol et al.   PLoS Computational Biology

First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

(2014) Benjamin J. Solomon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Patient-derived models of acquired resistance can identify effective drug combinations for cancer

(2014) Adam S. Crystal et al.   SCIENCE

The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer

(2014) L. Friboulet et al.   Cancer Discovery

Use of Collateral Sensitivity Networks to Design Drug Cycling Protocols That Avoid Resistance Development

(2013) L. Imamovic et al.   Science Translational Medicine

Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non–Small Cell Lung Cancer

(2013) Jim Sang et al.   Cancer Discovery

Mechanisms of Resistance to Crizotinib in Patients withALKGene Rearranged Non–Small Cell Lung Cancer

(2012) Robert C. Doebele et al.   CLINICAL CANCER RESEARCH

Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK-Positive Non-Small Cell Lung Cancer

(2012) J. Tanizaki et al.   CLINICAL CANCER RESEARCH

Collateral sensitivity as a strategy against cancer multidrug resistance

(2012) Kristen M. Pluchino et al.   DRUG RESISTANCE UPDATES

Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers

(2012) R. Katayama et al.   Science Translational Medicine

A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors

(2011) T. Sasaki et al.   CANCER RESEARCH

Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment

(2011) A. Becker et al.   EUROPEAN JOURNAL OF CANCER

Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer

(2011) Jin Ho Paik et al.   LUNG CANCER

EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors

(2010) Young Lim Choi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adaptive Therapy

(2009) R. A. Gatenby et al.   CANCER RESEARCH

Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK

(2009) Alice T. Shaw et al.   JOURNAL OF CLINICAL ONCOLOGY

Is resistance useless? Multidrug resistance and collateral sensitivity

(2009) Matthew D. Hall et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Evolution of Resistance to Targeted Anti-Cancer Therapies during Continuous and Pulsed Administration Strategies

(2009) Jasmine Foo et al.   PLoS Computational Biology